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Heterozygous loss of function of IQSEC2/Iqsec2 leads to
increased activated Arf6 and severe neurocognitive
seizure phenotype in females
Matilda R Jackson1,2, Karagh E Loring1,2, Claire C Homan2, Monica HN Thai1, Laura Määttänen3, Maria Arvio3,4,5 ,
Irma Jarvela6, Marie Shaw2, Alison Gardner2, Jozef Gecz2,7 , Cheryl Shoubridge1,2
Clinical presentations of mutations in the IQSEC2 gene on the
X-chromosome initially implicated to cause non-syndromic
intellectual disability (ID) in males have expanded to include
early onset seizures in males as well as in females. The mo-
lecular pathogenesis is not well understood, nor the mecha-
nisms driving disease expression in heterozygous females.
Using a CRISPR/Cas9–edited Iqsec2 KO mouse model, we
confirm the loss of Iqsec2 mRNA expression and lack of Iqsec2
protein within the brain of both founder and progeny mice.
Both male (52%) and female (46%) Iqsec2 KO mice present with
frequent and recurrent seizures. Focusing on Iqsec2 KO het-
erozygous female mice, we demonstrate increased hyperac-
tivity, altered anxiety and fear responses, decreased social
interactions, delayed learning capacity and decreased memory
retention/novel recognition, recapitulating psychiatric issues,
autistic-like features, and cognitive deficits present in female
patients with loss-of-function IQSEC2 variants. Despite Iqsec2
normally acting to activate Arf6 substrate, we demonstrate that
mice modelling the loss of Iqsec2 function present with in-
creased levels of activated Arf6. We contend that loss of Iqsec2
function leads to altered regulation of activated Arf6-mediated
responses to synaptic signalling and immature synaptic net-
works. We highlight the importance of IQSEC2 function for
females by reporting a novel nonsense variant c.566C > A,
p.(S189*) in an elderly female patient with profound in-
tellectual disability, generalised seizures, and behavioural
disturbances. Our human and mouse data reaffirm IQSEC2 as
another disease gene with an unexpected X-chromosome
heterozygous female phenotype. Our Iqsec2 mouse model re-
capitulates the phenotypes observed in human patients de-
spite the differences in the IQSEC2/Iqsec2 gene X-chromosome
inactivation between the species.
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Introduction
X-linked intellectual disability is a common, clinically complex
disease arising from mutations in more than 140 genes on the
X-chromosome (1), affecting between 1/600 and 1/1,000 males and
a substantial number of females (2). X-linked inheritance is more
complex than simply X-linked recessive or dominant (3) with both
X-inactivation (including associated tissue specific selection) and
the impact of individual mutations contributing to this complexity.
In mammals, the sex determination system used is XX/XY, with
dosage compensation in females as a result of random inactivation
of one of the two X chromosomes in every cell. As a consequence,
heterozygous females typically have a milder disease phenotype or
are not affected. Despite this, there is a growing list of X-chro-
mosome genes which are subject to X-inactivation or escape
X-inactivation, including, for example, PHF6, CLCN4, ALG13, ARX, or
USP9X, DDX3X, which display distinct phenotypes in males and
females depending on the functional severity of the variant, as well
as manifesting in a more severe female phenotype than the het-
erozygous state would predict (4, 5, 6, 7, 8, 9, 10). We contend that the
IQ motif and Sec7 domain 2 protein (IQSEC2) (NM_001111125) (MIM
300522) is another X-chromosome disease gene in which we see a
severe female phenotype because of heterozygous loss-of-function
mutation.
We previously implicated IQSEC2 as an X-linked intellectual
disability (XLID) gene through identification of variants in affected
males in four separate families (11). These missense variants were
clustered around the Sec7 and IQ-like domains and resulted in
reduced enzymatic activity (11). Clinical features within these non-
syndromic XLID families included moderate to severe intellectual
disability (ID) in all affected males, with variable seizures, autistic
traits, and psychiatric problems (11). Since then, unbiased, high-
throughput sequencing in ID and epilepsy cohorts have identified
familial and increasingly de novo loss-of-function IQSEC2 variants,
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typically leading to phenotypic outcomes, including severe ID with
epileptic encephalopathy, and a high prevalence of speech de-
velopment deficits and psychiatric features, including autistic
spectrum disorder. Interestingly, these severe phenotypes are
noted not only in affected males but also in affected, heterozygous
females (12). The mechanisms contributing to the disease severity,
particularly in heterozygous females is unknown and perplexing.
IQSEC2 is a guanine nucleotide exchange factor, which catalyzes
exchange of GDP for GTP in a number of ARF superfamily of proteins.
IQSEC2 is highly expressed in the forebrain, specifically localized to
excitatory synapses as part of the N-methyl-D-aspartate receptor
(NMDAR) complex (13, 14). The exact role IQSEC2 plays at excitatory
synapses remains unclear. Limited studies indicate a role in the
activity-dependent removal of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPAR) and activity-dependent
synaptic plasticity (15, 16). Our own studies have shown that IQSEC2
also has a fundamental role in controlling neuronal morphology (17).
However, there is currently no published research investigating the
impact of loss or altered Iqsec2 function on the development and
resulting cognitive outcomes in any animal model. It is not certain if
severe loss-of-function mutations in IQSEC2 can be transmitted in the
human setting, with only missense variants giving rise to milder non-
syndromic features beingmaternally inherited. Hence, it was unclear if
the loss of Iqsec2 function modelled in mice would survive into
postnatal life, be reproductively viable or useful to model disease
pathogenicity observed in humans. Here, we show that mice with the
complete loss of function of Iqsec2 by successfully targeting exon 3
using CRISPR/Cas9 technology survive into postnatal life and are vi-
able. In this study, we investigate the effect of severe loss-of-function
mutations driving the phenotype in patients, including the emerging
female-specific phenotype using a mouse modelling the KO of Iqsec2.
We present an elderly female patient with profound ID and gen-
eralised seizures with a novel loss-of-function IQSEC2 variant, pro-
viding important life span information for other patients diagnosed
with this typically early onset neurodevelopmental disorder. We re-
view the present literature of the growing number of females with
loss-of-function variants in IQSEC2, who have a more severe phe-
notype than the heterozygous state would predict. In humans, the
prevailing evidence suggests that IQSEC2 escapes X-inactivation (18,
19); however, inmice, Iqsec2 is subject to X-inactivation (20). Hence, the
mouse modelling heterozygous KO of Iqsec2 provides an opportunity
to assess the impact of X-inactivation and altered Iqsec2 gene dosage
in females. Here, we show that the loss of Iqsec2 function in mice
recapitulates key aspects of the human phenotype, irrespective of the
X-inactivation status of the gene in the two species, highlighting that
our understanding of the traditional X-chromosome inheritance with
heterozygous female sparing needs to be revisited.
Materials and Methods
Animal generation
All animal procedureswere approved by the Animal Ethics Committee
of The University of Adelaide, Adelaide, Australia, and undertaken in
accordance with their regulatory guidelines. Founding Iqsec2 KOmice
were generated by CRISPR/Cas9 by the South Australian Genome
Editing facility (SAGE), University of Adelaide, Adelaide; details given
below. Mice were maintained in the C57Bl/6N-Hsd background. An-
imals were of same sex and housed in individually ventilated cages,
with sterile food and water available ad libitum. Iqsec2 KO hemi-
zygous male founder A was bred with a wild-type female to generate
Iqsec2 KO heterozygous progeny, which were subsequently bred with
a wild-type stud male to generate Iqsec2 KO hemizygous, Iqsec2 KO
heterozygous, and wild-type littermates. Iqsec2 KO hemizygousmales
(n = 46) and Iqsec2 KOheterozygous females (n = 153) weremonitored
and scored daily (from postnatal day [P] 14) for general health and
welfare, appearance, weight, and the presence of seizure activity. In
addition to standard food available ad libitum, crushed chow was
soaked in sterile water and placed in an easily accessible feeding
dish, which was refreshed daily.
CRISPR/Cas9 guide design
Guides were designed by the SAGE facility, University of Adelaide,
under the guidance of Professor Paul Q Thomas as part of a fee for
service for the generation of CRISPR/Cas9 Iqsec2 KO mice. The
online tool (http://crispr.mit.edu/) was used to search for ap-
propriate CRISPR guide sites targeting the removal of Iqsec2 exon 3.
The most appropriate guide was determined by total score, cut site
in target gene, and number of off-target mismatches. Guides’
sequences determined most suitable were upstream CRISPR guide
59-TCTAGTGTACTCACTCAGTT-39 and downstream CRISPR guide 59-
AGGCTGGAACTGGCGAAAAC-39. The CRISPR/Cas9 complex will cause
double strand breaks in intron 2–3 of Iqsec2 and intron 3–4, causing
exon 3 to be deleted by a process of non-homologous end joining.
CRISPR gRNA generation, microinjections of zygotes, and transfer to
pseudopregnant recipients were performed by the SAGE facility as
previously described (21, 22, 23).
Genotyping
A small segment of toe tissue was removed by sterile technique at P5
from all pups for genotyping and identification purposes. Genomic
DNA was extracted as per the manufacturer’s instructions for Phire
Hot Start II DNA polymerase (Thermo Fisher Scientific). Genotyping
PCR was performed using 10 μM forward and reverse primer pairs
(Table S1), 2x Phire Tissue Direct PCRMaster Mix, andmade up to 20 μl
with MilliQ water. Reactions were placed in a thermocycler for one
cycle at 98°C for 5min, 32 cycles at 98°C for 30 s, 62°C for 30 s, 72°C for
1 min, and one cycle at 72°C for 1 min. PCR products were held at 4°C
before visualising on a 1.5% (wt/vol) agarose gel with 0.2 μg/ml
ethidium bromide in TBE buffer (1.1 M Tris, 900mM borate, and 25 mM
EDTA, pH 8.3) alongside 1 kb+ molecular weight marker. Images were
captured on a SynGene UV dock at 400 ms exposure on GeneSnap
v7.05 for SynGene. DNA sequencing analysis was performed using
SeqMan Pro version 10.1.2 (DNASTAR, Inc) against Iqsec2 cDNA ref-
erence sequence NM_001114664.
Analysis of Iqsec2 mRNA and Iqsec2 protein
Animals were humanely killed by cervical dislocation. Brain was
dissected from the skull and cut into two halves sagittally along the
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cerebral fissure. The right-hand side brain was separated and
minced into cortex (n = 2, one each for protein and RNA) and
cerebellum, snap-frozen in liquid nitrogen, and stored at −80°C
pending analysis. RNA was extracted from 40 mg homogenised
brain cortical tissue in TRIzol reagent and converted to cDNA using
SuperScript RT (Thermo Fisher Scientific) as described previously
(24). Iqsec2 gene expression was performed using both RT-PCR and
qPCR. RT-PCR was performed using 50 pmol forward and reverse
primer pairs (Table S1), 20U Roche Taq DNA polymerase, FailSafe
PCR 2X PreMix J (Epicentre), and made up to 50 μl with MilliQ water.
Reactions were placed in a thermocycler for one cycle at 94°C for 2
min, 35 cycles at 94°C for 30 s, 57–60°C for 30 s, 72°C for 30 s, and one
cycle at 72°C for 5 min. Images were captured as described above.
qPCR was performed using TaqMan gene expression assay probes
(Thermo Fisher Scientific) spanning exon 3–4 boundary
(Mm02344188_m1), exon 11–12 boundary (Mm02344183_m1), and
exon 13–14 boundary (Mm02344185_m1) with gapdh used as a
housekeeper (Mm99999915_g1). Wild types were pooled and av-
eraged based on sex (n = 4 female wild type, n = 5 male wild type).
Each individual Iqsec2 KO hemizygous male or heterozygous female
sample was normalised to the averaged wild-type data for their
respective sex, with resulting data displayed as relative Iqsec2
expression to their respective sexed wild-type controls. Protein
extraction, SDS–PAGE, and Western blot analysis of protein levels
were performed as described previously (17). The primary anti-
bodies were rabbit anti-IQSEC2 (1:2,000) as previously described
(17), rabbit anti-IQSEC1 and rabbit anti-IQSEC3, both used at 1:1,000
(Invitrogen), and mouse β-actin (AC-74; 1:20,000; Sigma-Aldrich
A2228). Secondary antibodies from DAKO (Santa Clara) were goat
antimouse HRP (1:2,000 P0447) and goat antirabbit HRP (1:2,000
P0448). Images were imported into Image Studio (Li-Cor Bio-
sciences), and band intensities of Iqsec proteins were normalised
to their respective β-actin loading control, and where required were
harmonized across multiple immunoblots using a consistent
control sample. Each individual Iqsec2 KO hemizygous or hetero-
zygous sample was normalised to the averaged pooled wild-type
data for their respective sex, with relative intensities presented (n
for each as described in figure legends).
Behavioural assessment
Iqsec2 KO heterozygous and wild-type females underwent monthly
behavioural testing from one to 6 mo of age (n = 4 Iqsec2 KO
heterozygous and n = 3 wild-type controls at 1 mo, n = 8 Iqsec2 KO
heterozygous, and n = 6 wild-type controls at all other time points)
as previously described (25).
Neuroanatomy
The left-hand side brain, separated along the cerebral fissure, was
fixed at 4 degrees in 10% neutral buffered formalin overnight,
before being washed three times in cold PBS, and stored in 70%
ethanol at 4 degrees. The samples were processed and paraffin-
embedded by the Adelaide University Histology Department. Semi-
serial sections, measuring 10 μm thick, were collected using a
strategy of mounting every fifth serial section across five slides
(series 1–5) with up to five replicates of this strategy per sample
(A–E) to span the breadth of the mouse brain in sagittal or coronal
orientation. The sections were stained by haematoxylin and eosin
or Nissl and scanned using a Hamamatsu NanoZoomer 2.0-HT
whole slide imager (Meyer Instruments). Images were imported into
ImageJ (Fiji; version 2.0.0-rc-59/1.51k, build fab6e1a004) for pro-
cessing and measurement.
Multielectrode array
Cortical neuronal were isolated from embryonic day (E) 17.5 Iqsec2
KO heterozygous female (n = 12) and wild-type littermates (n = 7
female) as per Hinze et al (17). Neuronal suspensions were plated at
2.97 × 105 cells/well on 0.1% polyethyleneimine/20 μg/ml laminin-
coated 24-well glass bottomed multielectorde array (MEA) plate
(product: 24W300/30G-288; MultiChannel Systems). After 21 d in
culture, 15-min recordings were captured using MultiScreen (version
1.5.9.0; MultiChannel Systems) at a sampling rate of 20,000Hz and 1,000
ms baseline duration. Spike binning was performed at 100-ms in-
tervals, with minimum burst duration set at 50 ms, with a minimum
spike count in burst set at four spikes. Captured data were uploaded
and exported using MultiAnalyser (version 1.2.90; MultiChannel Sys-
tems). Data obtained fromeach individual Iqsec2 heterozygous female
embryo was normalised to the averaged wild-type data.
G-LISA Arf6 activation assay
Protein was extracted from snap-frozen cortical tissue of wild-type
malemice (n = 4), KOmale mice (n = 6), wild-type femalemice (n = 5)
and HetKO female mice (n = 9) following the manufacturer’s in-
structions for use in a G-LISA Arf6 Activation assay Biochem Kit
(absorbance based) (Cytoskeleton). The levels of activated Arf6
measured in the cortical tissue were from mice ranging in age from
2 to 9 mo. Each sample was measured with an n = 4 replicates.
Within each assay, the levels of activated Arf6 measured in the wild-
type animals for each sex was set to 1, and values for each of the KO
or HetKO samples were determined relative to these age and sex-
matched wild-type controls. The relative levels of activated Arf6 for
all WT animals measured in a single assay were used to normalise
activated Arf6 levels across multiple assays. An aliquot of protein
from each cortical sample analysed in the GLISA assays was also
prepared for SDS–PAGE and Western blot analysis and probed for
Iqsec2 as described (17) and Arf6 protein abundance using poly-
clonal Arf6 antibody (PA1-093; Thermo Fisher Scientific) and
quantitated as indicated above for Iqsec2 protein abundance.
Molecular analysis of IQSEC2 variant
The screening protocols were approved by the Women’s and
Children’s Health Network Human Research Ethics Committee and
the Human Ethics Committee of The University of Adelaide, Ade-
laide, Australia (approval number REC2361/03/2020) and conforms
with the principles set out in the WMA Declaration of Helsinki and
Australian National Statement on Ethical Conduct in Human Re-
search (2018). Informed consent was obtained from carers of the
patient, including consent to publish images. DNA from the affected
female was whole-exome sequenced on an Illumina HiSeq2500 by
the Australian Genome Research Facility. Reads were mapped to
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Figure 1. CRISPR/Cas9 targeting of Iqsec2 resulted in absent (KO males) or reduced (KO HET females) Iqsec2/Iqsec2 expression.
(A) Schematic of the exon–intron structure of Iqsec2 long (NM_001114664) and short (NM_001005475) isoforms, with the dashed box indicating consensus sequence.
Zoomed-in schematic of Iqsec2 exon 2–4 (exon 2 long = 2L and exon 2 short = 2S) with CRISPR guides (arrows) flanking exon 3 (diagonal line fill), resulting in a predicted
445-bp deletion. Actual deletion size (highlighted by an orange box) shown flanking CRISPR guide putative cut sites in Founder A, with sex and total deletion size shown on
left-hand side. (B) RT-PCR amplification of exon 2/3 boundary, exon 1 (short isoform), and exon 1 (long isoform) to exon 4 of 3 male founders, and subsequent progeny
from founder A. (C) qPCR of three founder males (grouped) and subsequent progeny from founder A. Results are expressed as mean relative expression (±SEM; n = 3
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the human genome (hg19) using BWA-MEM (26) and mapping re-
fined using Genome Analysis Toolkit version 3.5 (27). Mapping
achieved a minimum median target coverage depth of 49 reads/
sample and covered 87.67% of intended targets with at least 20
reads. Single-nucleotide variants and small insertions and de-
letions were called by the genome analysis toolkit haplotype caller
version 3.5 (27). Whole-exome sequencing data are available upon
request.
All variants were annotated for allele frequency, clinical signifi-
cance, locus identity, and likely pathogenicity using ANNOVAR (28).
Statistical analysis
The statistical significance (P < 0.05) of the difference between
means of each strain, namely, Iqsec2 KO hemizygous males, Iqsec2
KO heterozygous females, and their respective age-matched con-
trol littermates, was determined using multiple statistical means. A
one-way ANOVA followed by Tukey’s HSD post hoc test was used for
qPCR and MEA analysis, whereas a two-way ANOVA followed by
Tukey’s HSD was used to assess behavioural differences across
time. A two-tailed, unpaired t test was used to compute statistical
significance of the difference between means for the GLISA anal-
ysis, and when wild-type littermates were omitted from statistical
analysis (seizure propensity). All data analyses were performed
using GraphPad Prism version 7 (GraphPad Software Inc.).
Results
Generation of loss-of-function Iqsec2 KO mice by CRISPR/Cas9
deletion of exon 3
Generation of a knockout (KO) mouse line to model the loss of
Iqsec2 function was achieved by targeting exon 3 of Iqsec2 for
deletion by CRISPR/Cas9 editing (17). The sequence and targeting of
CRISPR guides to remove exon 3 in both isoforms are detailed in Fig
S1. Exon 3 is invariable between the two main isoforms of Iqsec2,
with exons 3–13 comprising consensus sequence (Fig 1A). Injection
of the CRISPR/Cas9 guides was performed as a fee for service
(South Australian Genome Editing facility, University of Adelaide,
Adelaide) (21). PCR amplification of genomic DNA (Fig S2A) and
subsequent breakpoint mapping and sequencing of amplicons
demonstrate that Founder A (male) had exon 3 removed with
neighbouring exon 2 (short and long isoforms), exon 4, and exon 5
unaffected by the deletion, demonstrating successful targeted
deletion of exon 3 (Fig 1A). Although exon 3 did not amplify in any of
the four founders generated (Fig S2B), founders B and C (males) had
larger deletions than expected (Fig S2A), both impacting exon 4, and
founder D (female) had a homozygous deletion of exon 3 (Fig S2C).
The homozygous loss of IQSEC2 has not been reported in the human
population. Given the increasing incidence of mutations in girls
(heterozygous) with early-onset seizure phenotypes, it was not
unexpected that this female homozygous KO mouse was found
dead early in postnatal life, negating the opportunity to collect
samples for expression analysis, or attempt breeding. This animal
was not included in any further analysis. Overall, the editing of all
founders extended past the recognised CRISPR/Cas9 guide cut sites
in both directions by nonstandard amounts, with larger deletion
sizes of this X-chromosome region noted in males. This finding
demonstrates that CRISPR/Cas9, although an effective genome
editing tool, requires careful validation.
To confirm that deletion of exon 3 by CRIPSR/Cas9 editing
resulted in loss of Iqsec2/Iqsec2, we analysed the gene expression
and protein level from cortical brain tissue in which Iqsec2 is highly
expressed during postnatal life. We demonstrate in the three
founder males and progeny of founder A that Iqsec2 expression was
reduced or absent when detected by RT-PCR (Fig 1B) and signifi-
cantly reduced compared with sex-matched wild-type progeny
when analysed by qPCR (Fig 1C). Founder A and founder B had no
detectable Iqsec2 expression by either analysis. The negligible
expression levels of Iqsec2 short isoform detected for founder C in
the RT-PCR analysis was not replicated by qPCR. Iqsec2 KO hemi-
zygous male progeny from founder A also had no detectable Iqsec2
expression by RT-PCR (Fig 1B) but demonstrated minimal Iqsec2
expression by qPCR with the probe spanning across the exon 11–12
boundary Fig 1C. (ii) This result is consistent with very low levels of
transcript (~5% of normal) being present before nonsense-
mediated mRNA decay. Iqsec2 KO heterozygous female progeny
showed that Iqsec2 expression by RT-PCR for both the short and
long isoforms were reduced to less than half the levels of wild-type
female controls (Fig 1B). Similarly, reduced Iqsec2 expression in
these females was also noted by qPCR, with expression levels
dependent on the probe used (range 0–79%, mean 35%), but were
still significantly elevated above both founder males and Iqsec2 KO
hemizygous male progeny (Fig 1C). We note that expression levels
were quite varied between individual heterozygous females and
cannot discount differences due to levels of X-inactivation in these
animals. The threemale founders had no discernible Iqsec2 protein
in the cortex (Fig 1D). Similarly, there was no discernible Iqsec2
protein in KO hemizygous male progeny and reduced levels of
Iqsec2 protein (~half of the wild-type control levels) in KO het-
erozygous female progeny (Fig 1D). Off-target analysis of CRISPR/
Cas9 editing using computational tools (CRISPR design tool by MIT:
http://crispr.mit.edu/ and COSMID: https://crispr.bme.gatech.edu)
identified that the majority (92%) of predicted off-targets were
located in regions that did not harbour genes or impacted intronic
regions within genes and were unlikely to effect the coding region
founders, n = 6 Iqsec2 KO hemizygous males (KO), n = 6 Iqsec2 KO heterozygous females [HET]) normalised to wild types, which were pooled and averaged dependent on
sex (n = 4 female wild type, n = 5 male wild type). (C) TaqMan gene expression assay probes spanning (i) exon 3–4 boundary, (ii) exon 11–12 boundary, and (iii) exon 13–14
boundary with gapdh used as a housekeeper. (D)Western blot analysis of Iqsec2 and Iqsec3 expression in three founder males and subsequent progeny from founder A.
Blots were imported into Image Studio (Li-Cor Biosciences) and band intensities normalised to their respective beta-actin (Actb) loading control. Wild types were
pooled and averaged dependent on sex (n = 2 female wild type, n = 2male wild type). White spaces indicate a cropped image. # indicates significant difference between HET
and founder, P < 0.0001 one-way ANOVA, Tukey’s HSD, ^ indicates significant difference between HET and KO, P < 0.0001; one-way ANOVA, Tukey’s HSD.
Heterozygous loss of function of IQSEC2 Jackson et al. https://doi.org/10.26508/lsa.201900386 vol 2 | no 4 | e201900386 5 of 18
of the genome (Table S2). For the 31 genes identified to potentially
be impacted by off-target effects, 28 were reported with high
numbers of mismatch (n = 4). In contrast, Iqsec3 was the only gene
predicted to be impacted by either CRISPR guide that was identified
by both computational tools (Table S2). IQSEC3 is highly expressed
within multiple regions of the brain, including the cortex. Our
analysis of the three founder males demonstrates that Iqsec3
protein levels in the cortex were reduced (27%, 14%, and 36% of
wild-type, respectively) but were normalised to wild-type levels in
subsequent founder A progeny (Fig 1D). Taken together, these data
suggest successful outbreeding of the potential off-target effects.
To investigate if the loss (or partial loss) of Iqsec2 protein in the
Iqsec2 KO mice elicited a compensatory effect by other members of
the Iqsec protein family, we measured the protein abundance of
Iqsec1 and Iqsec3 in cortical samples of the wild-type and Iqsec2 KO
mice by immunoblot. The levels of Iqsec1 protein were very low
compared with the ready detection of Iqsec3 protein in the same
samples and were not robust enough for semiquantitative analysis.
Despite this, we did not see any empirical evidence of a consistent
or stronger signal in the Iqsec2 KO animals. In the case of Iqsec3,
there was no significant increase in protein abundance in the
brains of Iqsec2 KO hemizygous male or KO heterozygous female
mice compared with wild-type sex-matched mice (Fig S3). Hence,
we demonstrate that Iqsec protein family members are unlikely to
provide a compensatory role to ameliorate the loss or partial loss of
Iqsec2.
Iqsec2 KO male and female mice present with spontaneous
seizures
We observed severe spontaneous seizures in both Iqsec2 KO
hemizygous male and heterozygous female mice modelling loss of
Iqsec2 function. We saw a combination of four seizure subtypes that
although distinctive in appearance, were often observed in a single
seizure episode in both sexes. The seizures included (i) sudden
onset of irregular generalised clonic jerks, where the mouse
demonstrated involuntary, uncontrolled, unilateral head move-
ments (Video 1); (ii) repetitive forelimb clonus that commenced with
intermittent clonic jerking of the head and forelimbs, which then
became rhythmic, associated with tonic posturing of the forelimbs,
evolving to rearing and generalised tonic–clonic activity lasting ~60 s
(Video 2); (iii) uncontrolled convulsions with bilateral forelimb
Figure 2. Iqsec2 KO hemizygous males and
heterozygous females exhibit spontaneous
seizures and reduced survival, which was not
observed in their wild-type control littermates.
The total number of animals phenotyped include KO;
n = 46 (blue) and HET; n = 153 (pink). (A, B, C, D, E)
Percentage seizure occurrence and (B) survival
presented at daily intervals from birth, with both
further subclassified as (C) age at observed first
seizure, (D) age at unexpected death, and (E) occurrence
of repeat seizures presented as median (±min/max),
where each dot represents an individual animal.
Unexpected death was classified as humane euthanasia
or found dead presumed because of seizure or status
epilepticus and does not include those individuals
taken for experimental end point. These data do not
include any movement phenotypes observed. (F)
Iqsec2 heterozygous females (Het/pink; n = 13) have
reduced levels of Iqsec2 protein compared with female
wild-type animals (WT/grey; n = 11). Mean (±SEM) data
presented. The animals with observed seizures are
denoted as stars. There were no significant differences
in Iqsec2 protein abundance between male (WT/
Black; n = 10) and female wild-type animals (WT/grey; n =
11). * indicates significant difference between KO males
and HET females, P < 0.05, two-tailed, unpaired t test,
# indicates P < 0.0001, two-tailed, paired t test, ^
indicates P < 0.05 between HET/KO and female WT
controls, two-tailed, unpaired t test.
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outward stretching were also noted which commenced with the
sudden onset of irregular generalised clonic jerks followed by
hypermotor activity, which lasted ~5 s before ceasing (and often
reinitiating; Video 3); and (iv) and full body tonic–clonic seizures
that started with symmetrical tonic extension of both forelimbs and
hindlimbs, which develop into rhythmic generalised clonic activity
after ~15 s, continuing for an additional 30 s before ceasing (Video
4). Seizure episodes were frequently accompanied by twitching
ears, a straight tail, and an increase in facial grooming/washing
pre- and post-seizure occurrence. Iqsec2 KO mice that were found
dead in their cage were classified as having died because of either a
seizure or status epilepticus, as no wild-type control littermates
were found dead in this study.
In concordance with the clinical variability noted in both male
and female human patients with loss-of-function mutations, we
measured large variations in age of onset, seizure severity, and
progression amongst individual Iqsec2 KO mice. The proportion of
Iqsec2 KO hemizygous males exhibiting seizures (all sub-types
combined) from birth to 4 mo of age (7–54%, respectively) was
significantly increased when compared with heterozygous females
(2–37%, respectively; Fig 2A). However, after 5 mo of age, the pro-
portion of Iqsec2 KO mice exhibiting seizures plateaued, with males
ranging from 57 up to 65% at the study end point (~300 d of
postnatal life) and females ranging from 54 to 60% across the same
time period. The survival from birth to 3 mo of age in Iqsec2 KO
hemizygous males (87%) was significantly decreased compared
with heterozygous females (91%; Fig 2B). From 4mo of age, Iqsec2 KO
males reached a plateau (80%), whereas survival of heterozygous
females continued to significantly decline until 8 mo of age (69%).
The first observed seizure occurred with similar timing in both
Iqsec2 KO male and female mice, at postnatal day (P) 29 and P23,
respectively (Fig 2C), with the first unexplained death occurring at
P16 and P7, respectively (Fig 2D). The majority of male (52%) and
female (46%) Iqsec2 KO mice were observed to have only one
seizure. The proportion of mice observed to have two or more
seizures spanning their postnatal life were similar between male
and female KO mice (13% and 2% versus 12% and 3%, respectively;
Fig 2E). The levels of Iqsec2 protein abundance in cortical tissue
Figure 3. Iqsec2 KO heterozygous females display
altered anxiety, increased locomotor activity and
reduced spatial learning and memory.
(A, B, C, D, E, F, G) Behavioural tests undertaken at
monthly intervals between 1 and 6 mo of age show
that Iqsec2 KO heterozygous females (HET/pink) (n = 4
at 1 mo; n = 8 at 2–3 mo, n = 7 at 4–6 mo) compared with
their wild-type female controls (WT/grey) (n = 3 at
1 mo; n = 6 at 2–6 mo) demonstrate (A) increased speed
across multiple apparatus (sociability apparatus
shown), (B) increased exploratory behaviour in the
open field test, (C) increased anxiety in open field test,
(D) decreased fear response in the elevated zero maze,
(E) reduced total interaction time in the sociability
apparatus regardless of familiar or novel cage
occupant, (F) decreased novel recognition in the
Y-maze, (G) and reduced spatial learning in the
Barnes maze (conducted at 6 mo of age). Mean (±SEM)
data presented, where * indicates significance between
HET/KOandWT controls, # indicates significant between
HET time points, two-way ANOVA with Tukey’s HSD.
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were reduced in heterozygous female mice compared with wild-
type female littermates (1.8 fold, P = 0.0264) as measured by
semiquantitative immunoblot (Fig 2F). Iqsec2 protein abundance
was not impacted by the presence of an observed seizure (in-
dicated by stars instead of circles).
Iqsec2 KO heterozygous female mice demonstrate altered
behavioural phenotyping
Given the striking similarity in the seizure phenotype displayed by
the Iqsec2 KO hemizygous male and heterozygous female mice,
coupled with the marked overlap in phenotypic outcomes in loss-
of-function male and females patients in the human setting, we
contend that the Iqsec2 KO heterozygous females provide a rep-
resentative model for this disorder. Interestingly, the male KO
progeny were able to breed and transmit the loss-of-function
Iqsec2 mutation with minimal difficulty. In contrast, the Iqsec2
KO heterozygous females displayed reduced breeding success (Fig
S4). However limited, this indicates that a loss-of-functionmutation
in Iqsec2 is able to be transmitted, at least in mice. Due largely to
the limited breeding success of our Iqsec2 KO heterozygous fe-
males, generating the required number of age appropriate KO
males for behavioural testing was challenging and precluded
testing in hemizygous males. Hence, we undertook a battery of
behavioural tests at monthly intervals up to 6 mo of age in the
Iqsec2 KO heterozygous females compared with female wild-type
controls.
Iqsec2 KO heterozygous females demonstrate an increased lo-
comotor activity and exploratory behaviour. Iqsec2 KO heterozy-
gous females exhibit reduced neuromuscular strength at 3, 5, and 6
mo of age using the inverted grid test (Fig S5A). Although the
difference in overall performance by each genotype on the ap-
paratus was significant (P = 0.0031), the variability amongst in-
dividuals meant that significance was not reached at any individual
time point. Hyperactivity was indicated by a significant (P < 0.0001)
increase in the overall average speed (Fig 3A; sociability apparatus
shown), and overall total distance travelled (Fig 3B; open field test
shown) compared with wild-type littermates onmultiple apparatus.
Figure 4. Neuroanatomy changes in Iqsec2 KO mouse brains.
(A, B) Nissl staining of brain sections in both (A) coronal and (B) sagittal orientations from adult wild-type and heterozygous KO females demonstrate there is no gross
disturbance to brain morphology. Scale bars shown for each set of pictomicrographs. (C) The thickness of the corpus callosum (CC) measured where the (1) start and (2)
end of the cingulum intercepts the CC in three coronal sections for each of n = 4 animals per genotype is significantly thinner in heterozygous female (HET/pink) mice
compared with wild-type female (WT/Grey) mice. (D) Heterozygous females have increased total hippocampal and dentate gyrus volume compared with wild-type
littermates (n = 4 each). (E) The area of the brain was measured in animals from 60 to 155 d postnatal age in sagittal sections in HET/pink and WT/grey females (a total 36
sectionsmeasured per genotype: nine sections each for n = 4 animals). The Iqsec2HetKO animals with observed seizures are denoted by stars. Mean (±SEM) data presented
where # indicates P < 0.001, and # # indicates P < 0.0001, two-tailed, unpaired t test between wild-type and heterozygous females.
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Altered anxiety and fear response was also noted in Iqsec2 KO
femalemice, with a significant increase in percentage total distance
travelled in the inner third of the open-field apparatus (Fig 3C and P
= 0.0006), increased number of head dips on the elevated zeromaze
(Fig 3D and P < 0.0001), and an initial increase in percentage total
distance travelled in the open arms of the elevated zero maze (Fig
S5B and P = 0.0007). This is in comparison with wild-type females,
which from 4 mo of age travelled a greater percentage of total
distance on the open arms of the elevated zero maze, suggesting
habituation (Fig S5B).
Normal social interaction and memory recall is demonstrated by
mice choosing to interact with a mouse rather than an empty cage
and a preference to interact with a novel mouse over a familiar
mouse when tested in a three-chamber sociability apparatus. The
Iqsec2 KO heterozygous females displayed autistic-like behaviour
evident by a significant decrease in the total overall time of in-
teraction, regardless of the other cage occupant (Fig 3E and P <
0.03). In addition, the behaviour of the Iqsec2 KO heterozygous
females suggests reduced learning capacity and spatial memory
retention in contrast to wild-type females. Iqsec2 KO heterozygous
females had a significant preference toward exploring the familiar
arm of the Y-maze increasing over time (Fig 3F and P = 0.0261) and
took significantly longer and travelled further distance to find the
escape hole in the Barnes maze (Fig 3G and P < 0.0265).
Altered neuroanatomy in Iqsec2 KO heterozygous female mice
Nissl stain of both the coronal (Fig 4A) and sagittal (Fig 4B) ori-
entations demonstrate there is no gross disturbance to the overall
anatomical structure of the brain in heterozygous female compared
with wild-type mice. Emerging evidence suggests that severely
affected patients with IQSEC2 loss-of-function mutations display a
phenotype that includes thinning of the corpus callosum. We ex-
amined the thickness of the corpus callosum at two distinct points,
each in three semi-serial coronal sections from an n = 4 animals per
genotype (sections relative to the reference Allen Brain Atlas,
Mouse, P56, and coronal images 44–46 of 132). Using this approach,
we demonstrate that the thickness of these regions was signifi-
cantly diminished in the heterozygous female mice compared with
the wild-type female mice (Fig 4C). In line with the increase in
Figure 5. Embryonic (E)17.5 cultured cortical neurons
from Iqsec2 heterozygous females (HET/pink; n =
449 electrodes from n = 12 embryos) exhibit hallmarks
of immature synaptic networks when compared with
their respective wild-type (WT) control littermates
(WT female/grey n = 256 electrodes from n = 7
embryos).
(A, B, C, D) Representative raster plots for (A.i) WT
female and (A.ii) HET female after 21 d in culture.
Quantitatively, HET cultures showed an increased (B)
spike count, (C) burst count, and (D) mean burst
duration compared with wild-type control littermates.
Mean (±SEM) data presented, where * indicates
significance between HET and WT control, two-tailed,
unpaired t test , where P < 0.05.
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hyperactivity and anxiety noted in our Iqsec2 KO heterozygous
females, we observed an increase in total hippocampal volume in
heterozygous KO female mice (34%, P = 0.0008 HET versus WT fe-
males) and an increase in the volume of the dentate gyrus (48%, P =
0.0006 for HET females) shown in Fig 4D (sections relative to the
reference Allen Brain Atlas, Mouse, P56, sagittal images 9–10 of 21).
Despite these discreet changes to specific neuroanatomical regions
of the brain, our analysis indicates there were no significant dif-
ferences in the area of the brain sections measured between wild-
type females and the heterozygous KO females (Fig 4E) (sections
relative to the reference Allen Brain Atlas, Mouse, P56, sagittal
images 11–12 of 21).
Iqsec2 female mice display hallmarks of immature synaptic
networks ex vivo
To investigate the impact of Iqsec2 on the activity of synaptic
networks, we analysed cultured cortical neurons using a multi-
electrode array. Neurons isolated from individual Iqsec2 KO het-
erozygous female embryos grown for 21 d in culture display
hallmarks of immature synaptic networks when compared with
neurons from wild-type littermates (Fig 5). Burst activity and
bursting behaviour is considered one of the most important
properties for analysing synaptic plasticity and information pro-
cessing within the central nervous system. Wild-type cultures
demonstrated consistent, evenly spaced bursts of closely clustered
action potentials, suggestive of a highly synchronised culture (Fig
5A.i). In contrast, Iqsec2 KO heterozygous cultures showed aberrant
synchronicity; with action potentials not consistently clustered in
large bursts, but included smaller, randomly spaced events (Fig
5A.ii). In line with this observation, cultures from heterozygous
females exhibited significantly elevated spike count (121%; Fig 5B
and P < 0.0001), burst count (113%; Fig 5C and P = 0.0002), andmean
burst duration (114%; Fig 5D and P = 0.003), but no difference in
mean burst interval (Fig 5E) when compared with sex-matched
wild-type controls. It must be noted that large variations existed
in Iqsec2 KO heterozygous cultures, with some embryos dem-
onstrating burst patterning similar to that of their wild-type
counterparts.
Loss of Iqsec2 function leads to an increased level of activated
Arf6 in cortical tissues
There are multiple ArfGEFs, each with a conserved Sec7 domain
responsible for catalysing nucleotide exchange and activating
members of the small G protein Arfs. Hence, it was not clear what
impact the loss-of-function of a single ArfGEF would have on
regulating activated Arf-mediated responses to synaptic signalling
in vivo. As Iqsec2 is an ArfGEF particularly for the small GTPase Arf6,
we analysed the levels of activated (or GTP bound) Arf6 in cortical
tissues from individual mice of each genotype. There was no change
in the level of Arf6 activation with increasing postnatal age (range
2–9 mo), and although the levels of activated Arf6 were higher in
wild-type females relative to wild-type males, this difference was
not significant (1.5 fold; Fig 6A). In contrast, cortical tissues from
heterozygous females exhibited significantly elevated levels of
activated Arf6 (2.6 fold; P = 0.0186) when compared with sex-
matched and age-matched wild-type controls (Fig 6B). A similar
outcome was observed in cortical tissues from hemizygous males
with an elevated, although not statistically significant, level of
activated Arf6 (2.45 fold; P = 0.0536) (Fig 6B). The increases in ac-
tivated Arf6 levels in Iqsec2 KO hemizygous and heterozygous mice
were not reflected by a significant increase in Arf6 protein abun-
dance relative to wild-type for either sex (detected in the same [and
additional] cortical tissue) (Fig 6C). Nor was Arf6 protein abundance
impacted by the presence of an observed seizure (indicated by
stars instead of circles; P = 0.1009).
Heterozygous loss-of-function variant in IQSEC2 in a female with a
neurocognitive seizure phenotype
Here, we report an elderly, 68-yr-old female (II-2) (Fig 7A) with
severe-to-profound ID, early onset of seizures who is nonverbal,
Figure 6. The levels of activated Arf6 in cortical tissue are elevated because of
Iqsec2 KO.
(A) Biochemical assays to measure the levels of activated Arf6 (G-LISA)
undertaken in cortical tissues of animals across postnatal development between
2 and 9 mo of age show that (A) the levels of activated Arf6 in wild-type male
mice (WT/black) (n = 4) are elevated in age-matched wild-type female mice (WT/
grey) (n = 5). (B) Iqsec2 KO hemizygous males (KO/blue, n = 6) and heterozygous KO
females (Het/pink; n = 9) both display increased levels of activated Arf6
compared with the sex-matched wild-type controls listed above. (C) The
abundance of Arf6 protein measured by immunoblot was not significantly
different between any genotype groups. The Iqsec2 KO animals with observed
seizures are denoted by stars. Mean (±SEM) data presented, where * indicates
significance between WT female control and HET/KO, P < 0.05, 2-tailed, unpaired
t test.
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and communicates primarily using sounds and gestures. She has a
history of normal early development, learning to sit at 8–10 mo and
walk at age 18 mo. After seizure onset at 17 mo, she developed
repeated, generalised seizures during the daytime and regression
was observed. She later developed additional atypical absence and
atonic seizure types. Since the age of 11, she has been living in
residential care. Her daily functioning skills are poor, and she needs
assistance in every-day life. Facial features include low-set, large
ears, and asymmetric facial features with prominent angle of the
jaw, thick upper lip with mild hypertrichosis over the upper lip and
deep-set eyes (Fig 7B). No brain MRI has been performed because of
the requirement of general anaesthesia. A detailed clinical de-
scription of the proband is described in Supplemental Data 1.
Whole-exome analysis of four Finnish families identified a novel,
heterozygous single-nucleotide polymorphism at genomic position
ChrX:g.53,349,756 (GRCh37/19) in the female proband of one family.
The variant has been submitted to the gene variant database at
https://databases.lovd.nl/shared/genes/IQSEC2 (patient ID 00174867;
DB-ID #0000398628). Sanger sequencing confirmed the presence of
this variant in the proband (Fig 7C). Samples were not available for
the twin brother or parents of the affected female proband to
confirm the inheritance status of this variant. This variant in exon 1
of the NM_001111125.2 long isoform substitutes a single nucleotide
at c.566C>A, generating a predicted premature stop codon, p.(S189*)
(NP_001104595) in IQSEC2 (Fig 7D). This variant was not found in ExAC,
GnomAD, or dbSNP150 project databases. This predicted premature
stop codon is located 141 nucleotides from the exon 1–2 junction, with
the transcript predicted to be degraded via the nonsense-mediated
mRNA decay pathway, resulting in loss of the IQSEC2 protein.
Review of the literature shows that the affected female proband
adds to the growing number of affected females with loss-of-function
variants in IQSEC2 gene presenting with severe ID and early-onset
seizures (Table 1) (29–42) recently reviewed (12). Table 1 details 31
different variants in IQSEC2 in 38 separate cases of affected female(s)
predicted to cause pathogenic loss of IQSEC2 function. Of these 31
variants, 28 are known to have arisen de novo, one case of gonadal
mosaicism in a family of four affected girls, and one case of
monozygotic twins, with discordant phenotypes. The inheritance in
the proband of the current report was unable to be determined.
Although not all cases were accompanied by complete clinical de-
scriptions, 33 of the 38 cases report developmental delay or ID ranging
from mild-to-severe or profound and present with a range of
comorbid behavioural and psychiatric features (Table 1). Interestingly,
28 of the 38 cases reported a range of seizure types in the affected
females, including epileptic encephalopathies (Table 1). In a recent
review of the phenotypic spectrum of epileptic encephalopathies in
male and female patients with pathogenic IQSEC2 variants, it was
noted that there was no specific electroclinical syndrome that could
Figure 7. Identification of a c.556C > A
(NM_001111125.2) variant resulting in a premature
stop codon at p.(S189*) (NP_001104595) in IQSEC2.
(A) Pedigree of family. Open symbols represent
unaffected individuals and filled black circle
represents female with profound-to-severe
intellectual disability and epilepsy. Normal (N) and
mutant (M) alleles shown for proband. (B)
Asymmetrical facial features, prominent angle of the
jaw and low-set, large ears of II-2 (front and side).
(C) DNA sequence electropherograms for the chrX:
g.53349756 (GRCh37/hg19 assembly); c.556C>A mutation
in exon 1 of 15 of IQSEC2 in II-2 affected female.
(D) Predicted impact of novel variant in IQSEC2. The
exon–intron structure of the longest isoform of the
IQSEC2 gene (NM_001111125.2) with 15 exons, the ATG and
open reading frame and stop codon position in black
and 59 and -39 untranslated regions in light grey. The
predicted protein structures (NP_001104595) with
known functional domains highlighted; coiled–coiled
(CC-red), IQ-like (orange) Sec7 enzyme domain (Green),
PH domain (purple), and PDZ-binding motif (Blue),
corresponding amino acids listed below each
domain. The variant c.566C>A replaces the codon for
Serine (p.189) for a stop codon and is predicted to result
in nonsense-mediated mRNA decay and loss of the
protein from the mutant allele.
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Table 1. Pathogenic loss-of-function variants in IQSEC2 in females with intellectual disability and other comorbidities.
cDNA Ex Protein Dom Family DD/ID Seizures Behavioural/Psychiatric/Physical features Ref
c.55_151delinsAT 1 p.Ala19Ilefs*32 — P1 Mild ID None
Speech
deficits—pronunciation,
syntax issues at 6.5 years.
Tantrums, anxiety
(29)
c.83_85del 1 p.Asp28del CC 108286 Rett like None









screaming spells. Partial or
loss of spoken language.
(31)









c.804delC 3 p.Tyr269Thrfs*3 — 48 Seizures Limited phenotype reported. (32)
c.854del 3 p.Pro285Leufs*21 — P11 Severe ID Seizures (12 mo) tonic–clonic Says words at 16 years. Limbrigidity, walking instability. (29)
c.928G>T 3 p.Glu310* — P16 Mild-mod DD FE No ASD or other features.Nonverbal at 3 years. (33)
c.1556_1599delACCT 5 p.Tyr519Trpfs*87 — P10 DD, Severe toprofound ID None




c.1591C>T 5 p.Arg531* — P3 DD, Severe toprofound ID Tonic–clonic, absence




c.1744_1763del 5 p.Arg582Cysfs*9 — P16 Mild DD Focal epilepsy (17 mo)




c.1983_1999del 5 p.Leu662Glnfs*25 — P17 Global DD Focal epilepsy (11 mo) Babbling at 16 moHypertonia. (29)
c.2052_2053delCG 5 p.Cys684* — 47 Seizures Limited phenotype reported. (32)
c.2078delG 5 p.Gly693Valfs*29 P18 Mod globalDD None




c.2203C>T 5 p.Gln735* — T17563 Mild ID
SGE (5 years)—regression
with nonconvulsive SE.
Absence to tonic–clonic and
myoclonic seizures, drop
attacks. Offset at 38 years.
(35)
c.2272C>T 5 p.Arg758* — P19 Severe ID Multifocal epilepsy (23 mo) 3 words at 11.3 years. Self-injurious behaviours. (29)
P20 Mod ID Seizures (9 years 4 mo) GTCS,focal, atypical absences
Speaks sentences,
reasoning difficulties
c.2317C>T 6 p.Gln773* Sec7 P6 Global DD Seizures (18 mo) Hypotonic, strabismus,dysmorphic face (36)
P23 Mod ID Seizures (14 years), GTCS,absences
Few words at 43 years. ASD
(13 years) aggressive. (29)
c.2317_2332del 6 p.Gln773Glyfs*25 Sec7 P24 Seizures (6 years) Sentences at 11.3 years (29)
(Continued on following page)
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Table 1. Continued
cDNA Ex Protein Dom Family DD/ID Seizures Behavioural/Psychiatric/Physical features Ref
c.2679_2680insA 8 p.Asp894fs*10 Sec7 K2 DD, Mod-severe ID Epilepsy
4 affected sisters, nonverbal
(2), language delay (1),
aggressive when young and
ASD traits (2)
(37)
c.2776C>T 9 p.Arg926* Sec7 P3 Severe IDRett like EE
ASD (balance & hand
stereotypies), pain
sensitivity & aggressive.
Speech delay, regression at 2
years. Now nonverbal
(38)
P26 Profound ID LGS (23 mo)









delay, nonverbal at 14 years.
(39)
c.2854C>T 9 p.Gln952* PH P27 Severe ID EE (12 years), absences, GTCS




c.2911C>T 10 p.Arg971* PH P8 DD, Severe toprofound ID Seizures
No ASD. Stereotypies and
dysmorphic features. (34)
P11 DD, Severe toprofound ID Seizures





c.3079delC 11 p.Leu1027Serfs*75 PH P29 Mod-severeID None 10 words at 8 years (29)
c.3163C>T 12 p.Arg1055* PH Pat19 Severe ID Epilepsy Borderline macrocephaly,skewed X-inactivation (97:3) (40)
P31 Mod-severeID
Seizures (5 years 8 mo) GTCS,
focal dyscognitive
3 word sentences, and 20





c.3278C>A 13 p.Ser1093* — P36 Severe ID None Few words, rare sentences at13 years. (29)
c.3322C>T 13 p.Gln1108* — KO EE (41)
c.3433C>T 13 p.Arg1145* — P39 Severe ID Focal epilepsy (11 mo) focal,tonic, tonic–clonic
Nonverbal at 11 years.
Autistic behaviour. (29)
c.3457del 14 p.Arg1153Glyfs*244 — P40 Severe ID
IS (7 mo) spasms, focal,
absence, tonic, myoclonic
jerks
Nonverbal at 20 years.
Autistic behaviour, truncal
hypotonia. MRI mild atrophy
and cerebral white matter
hyperintensities.
(29)
c.4039dupG 15 p.Ala1347Glyfs*40 — 1098 M EE (19 mo) ASD, macrocephaly (42)
P41 Mild-mod ID Seizures (3 years) absenceand falls
Speaks sentences, writes




c.4401del 15 p.Gly1468Alafs*27 — P42 Mod-severeID None




(Continued on following page)
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be defined, with all patients displaying multiple seizure types con-
sisting mainly of atonic, myoclonic, or epileptic spasms. The seizure
phenotypes were accompanied with a variety of electroencephalo-
gram (EEG) patterning, including hypsarrhythmia, polyspikes and
waves, generalised spikes and waves, slow spikes and waves, as well
as background slowing (33). The advanced age of the female proband
(68 yr old) we identify and present as part of this study underscores
the importance of considering IQSEC2 as an explanation of ID and,
particularly, seizures in females across their life span. Furthermore,
this finding reinforces the fact that a female IQSEC2 phenotype may
still be under-ascertained.
Discussion
The cellular andmolecular pathogenesis of IQSEC2mutations is not
well understood. To address this, we used CRISPR/Cas9–targeted
editing to generate an Iqsec2 KO mouse model with no (Iqsec2 KO
hemizygous males) or reduced (Iqsec2 KO heterozygous females)
Iqsec2 mRNA and protein. We validated both successful genome
editing and germline transmission. To date, there have beenno reports
of transmission of loss-of-function mutations in IQSEC2 in the human
setting, with the exception of gonadal mosaicism in a family of four
affected female siblings (37). We demonstrate that hemizygous KO
males were viable and able to breed and generate healthy female
heterozygous KO offspring. This suggests a potential difference in
mouse to human phenotypic outcomes related to brain and sexual
development (43, 44). Despite some difficulties, the successful
breeding of the Iqsec2 KO heterozygous femalemice shows that a loss-
of-function mutation in Iqsec2 can be transmitted, at least in mice.
In agreement with the expanding phenotypic spectrum and the
67% penetrance of seizures in patients with de novo pathogenic
variants in IQSEC2 (33), we demonstrate that severe spontaneous
seizures are observed in approximately half of all the Iqsec2 KO
mice. In these mice, we observed four distinct seizure types: (i)
involuntary, uncontrolled, unilateral head movements, (ii) re-
petitive forelimb clonus, (iii) uncontrolled convulsions with bi-
lateral forelimb outward stretching, and (iv) full body tonic–clonic
seizures. Using the (human) International League Against Epilepsy
classification system, these seizures can be considered equivalent
to a (i) generalised clonic seizure, (ii) focal seizure evolving to
bilateral tonic–clonic seizure, (iii) focal motor seizure (likely frontal
lobe onset), and (iv) generalised tonic–clonic seizure (Personal
communication: A/Prof Nigel C Jones, Department of Neuroscience,
Central Clinical School, Monash University, Melbourne, Victoria,
Australia). Although EEG analysis was not undertaken in this study,
aberrant firing and abnormal burst activity was noted in neuronal
cultures of Iqsec2 KO affected embryos. This abnormal activity is
consistent with immature synaptic networks, previously associated
with neurodevelopmental disorders (45, 46, 47).
Ionotropic glutamate receptors are ligand-gated cation
channels that mediate most of the excitatory neurotransmission
in the brain and are classified based on pharmacological se-
lectivity to AMPA, kainic acid, and N-methyl-D-aspartic acid
(NMDA). Activation of these receptors couples the electrical signal
at the synapse to downstream biochemical signalling pathways.
Selected NMDAR subunit genes have been implicated in the
pathogenesis of ID (48, 49, 50). Synaptic plasticity associated with
changes to spine morphology has been shown to be dependent
on activation of these receptors (51, 52, 53, 54). IQSEC2 is localized
to excitatory synapses as part of the protein scaffold downstream
of the NMDA receptor complex. Through enzyme activity, IQSEC2
activates ARF6, a member of the Ras superfamily (55) to facilitate
downstream remodelling of actin cytoskeleton, a site of con-
vergence with other ID and autism genes. In the present study, we
demonstrate that neurons in culture isolated from individual
heterozygous female embryos display hallmarks of immature
synaptic networks. Investigating which critical components of
synaptic signalling are altered in response to Iqsec2 dosage, we
show surprisingly the loss of Iqsec2 leads to an increase in the
levels of activated Arf6 in cortical tissue during postnatal life. The
increase in the active form of Arf6 is independent of changes to
the overall abundance of Arf6 protein. Taken together, these data
indicate that increased levels of activated Arf6 in the presence of
Iqsec2 loss of function are likely to be at the local, dendritic
environment in response to neuron signalling. Using the novel
and powerful Iqsec2 KO hemizygous male and heterozygous fe-
male mouse models will enable further investigations into the
critical components altered in response to reduced Iqsec2 dosage
and the downstream events contributing to disease outcomes.
Review of the female patients with complete loss-of-function
mutations in IQSEC2 shows that comorbid behavioural and
Table 1. Continued
cDNA Ex Protein Dom Family DD/ID Seizures Behavioural/Psychiatric/Physical features Ref
c.4419_4420insC 15 p.Ser1474Glnfs* — P6 DD, Severe toprofound ID Absence, complex
Autism, hypotonia. First





Twin sister of P6 P7 DD, Mild ID No Autism, first words 11.5 mo.Ataxic gait
ASD, autistic spectrum disorder; DD, developmental delay; EE, epileptic encephalopathy; GTCS, generalised tonic–clonic seizures; IS, infantile spasms; SGE,
symptomatic generalised epilepsy.
Del, deletion; dup, duplication. Numbers (alone) in brackets indicate number of affected individuals.
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence for IQSEC2
(GenBank: NM_001111125.2).
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psychiatric features are frequently present in addition to ID (Table
1). Hence, it was not surprising that mice modelling Iqsec2 KO in the
heterozygous female state displayed a range of phenotypic traits
across a series of behavioural tests corresponding to these ad-
ditional features (Table 2). Notably, the Iqsec2 KO heterozygous
females recapitulated a reduction in intellectual functioning and
autistic-like behaviours, demonstrated through a loss of novel
recognition on the Y-maze, a reduction in learning and memory
during the Barnesmaze trial, and an overall reduction in interaction
time during the sociability test. Altered anxiety-like/fear responses
and hyperactivity in the Iqsec2 KO heterozygous female mice on
multiple apparatus correlate with an increase in hippocampal
volume, which has been associated with mental retardation and
psychiatric issues such as autism, attention-deficit disorder, and
schizophrenia (56, 57). We also observe a thinning of the corpus
callosum in the Iqsec2 KO heterozygous female mice, a phenotype
emerging in several cases (29). Taken together, these findings
highlight that our Iqsec2 KO mouse model recapitulates the
complex phenotypic spectrum observed in female patients with
loss-of function IQSEC2 variants (31, 32, 33, 35, 36, 37, 38, 39, 40, 41).
Interestingly, the emergence of a speech phenotype is noted in
the proband reported in this study and 26 of the 38 published
female cases with loss-of-function variants (Table 1). Although we
have not yet addressed this clinical feature in mice, it would be
interesting to investigate it, particularly in view of the observa-
tions of reduced mothering skills of the breeding heterozygous
females.
Female patients with de novo loss-of-function mutations in
IQSEC2 often have a more severe phenotype than the heterozygous
state would traditionally predict, particularly if IQSEC2 is thought to
escape X-inactivation. The capacity of genes on the X-chromosome
to be silenced, or to escape to some degree X-inactivation is not
fully understood. Escape from X-inactivation for IQSEC2 in humans
has long been the prevailing view, as demonstrated by evidence
measuring DNA methylation as a predictor of inactivation status
across a panel of 27 tissues from 1,875 females (58). In contrast,
recent large-scale expression studies from the GTEX consortium
demonstrate that the expression of IQSEC2 is similar in males and
females across a broad range of tissues, including regions of the
brain (19). This would suggest either dosage compensation in males
(up-regulation) or females (down-regulation) or X-chromsome
inactivation (XCI) in females. The degree by which incomplete XCI
manifests as detectable sex differences in gene expression and
phenotypic traits remains poorly understood (58, 59). The Iqsec2 KO
mouse model studied here shows severe phenotypic presentation
in the heterozygous state. This fact would suggest that the severity
of the phenotype in heterozygous females with loss-of-function
IQSEC2/Iqsec2 allele is generally independent of X-chromosome
inactivation. Given that X-inactivation leads to cellular mosaicism in
heterozygous females one may speculate that the function and
impact of IQSEC2/Iqsec2 is cell nonautonomous, that is, loss of
IQSEC2/Iqsec2 impacts wild-type (i.e., where the mutant X is
inactivated) as well as mutant (i.e., cells where the wild-type X is
inactivated) cells. As such, this genetic KO model will provide an
excellent tool to investigate the molecular mechanisms of X-linked
inheritance underpinning the male and female phenotypes, pro-
viding valuable information not only for Iqsec2, but other X-linked
genes with an emerging female phenotype (4, 5, 6, 37).
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